Market closed
Neumora Therapeutics/$NMRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neumora Therapeutics
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Ticker
$NMRA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
110
Website
NMRA Metrics
BasicAdvanced
$123M
-
-$1.53
-
-
Price and volume
Market cap
$123M
52-week high
$11.57
52-week low
$0.62
Average daily volume
1.2M
Financial strength
Current ratio
10.508
Quick ratio
10.292
Total debt to equity
0.646
Management effectiveness
Return on assets (TTM)
-40.50%
Return on equity (TTM)
-64.48%
Valuation
Price to book
0.43
Price to tangible book (TTM)
0.43
Price to free cash flow (TTM)
-0.657
Growth
Earnings per share change (TTM)
-57.84%
3-year earnings per share growth (CAGR)
-47.93%
NMRA News
AllArticlesVideos
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bronstein, Gewirtz & Grossman, LLC Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Accesswire·3 weeks ago
Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline
Accesswire·3 weeks ago
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Neumora Therapeutics stock?
Neumora Therapeutics (NMRA) has a market cap of $123M as of April 27, 2025.
What is the P/E ratio for Neumora Therapeutics stock?
The price to earnings (P/E) ratio for Neumora Therapeutics (NMRA) stock is 0 as of April 27, 2025.
Does Neumora Therapeutics stock pay dividends?
No, Neumora Therapeutics (NMRA) stock does not pay dividends to its shareholders as of April 27, 2025.
When is the next Neumora Therapeutics dividend payment date?
Neumora Therapeutics (NMRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Neumora Therapeutics?
Neumora Therapeutics (NMRA) does not currently have a Beta indicator.